Elsevier established a free COVID-19 resource centre in January 2020, offering information in English and Mandarin. The centre is hosted on Elsevier Connect, and Elsevier grants permission for free access to its research in PubMed Central and other repositories. The article discusses the potential use of baricitinib, a janus kinase inhibitor, as a treatment for 2019-nCoV acute respiratory disease. Baricitinib is predicted to reduce the virus's ability to infect lung cells by inhibiting AAK1, a protein involved in endocytosis. While several AAK1 inhibitors exist, they often have serious side effects. Baricitinib, however, is a high-affinity AAK1 inhibitor and is already approved for medical use. Its plasma concentration on therapeutic dosing is sufficient to inhibit AAK1, suggesting it could be trialled for 2019-nCoV. The article highlights the role of ACE2, a receptor used by 2019-nCoV to infect lung cells. Baricitinib also binds to cyclin G-associated kinase, another regulator of endocytosis. It could reduce both viral entry and inflammation in patients, using endpoints like the MuLBSTA score for predicting mortality in viral pneumonia. The study was conducted by BenevolentAI, which uses a knowledge graph to identify potential treatments. The authors note that their findings are preliminary and require further research. They emphasize the importance of ongoing investigations and the need for further detailed analysis. The study was authored by a team including Justin Stebbing, editor-in-chief of Oncogene, and colleagues from BenevolentAI and Imperial College London. The research was published in The Lancet. The article includes references to various studies and data sources.Elsevier established a free COVID-19 resource centre in January 2020, offering information in English and Mandarin. The centre is hosted on Elsevier Connect, and Elsevier grants permission for free access to its research in PubMed Central and other repositories. The article discusses the potential use of baricitinib, a janus kinase inhibitor, as a treatment for 2019-nCoV acute respiratory disease. Baricitinib is predicted to reduce the virus's ability to infect lung cells by inhibiting AAK1, a protein involved in endocytosis. While several AAK1 inhibitors exist, they often have serious side effects. Baricitinib, however, is a high-affinity AAK1 inhibitor and is already approved for medical use. Its plasma concentration on therapeutic dosing is sufficient to inhibit AAK1, suggesting it could be trialled for 2019-nCoV. The article highlights the role of ACE2, a receptor used by 2019-nCoV to infect lung cells. Baricitinib also binds to cyclin G-associated kinase, another regulator of endocytosis. It could reduce both viral entry and inflammation in patients, using endpoints like the MuLBSTA score for predicting mortality in viral pneumonia. The study was conducted by BenevolentAI, which uses a knowledge graph to identify potential treatments. The authors note that their findings are preliminary and require further research. They emphasize the importance of ongoing investigations and the need for further detailed analysis. The study was authored by a team including Justin Stebbing, editor-in-chief of Oncogene, and colleagues from BenevolentAI and Imperial College London. The research was published in The Lancet. The article includes references to various studies and data sources.